OTC · CLCS
Cell Source, Inc.
$0.53+$0.06 (+13.97%)
Cell Source, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.45% below the high.
Loading market information…
NASDAQ · PPCB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Propanc Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.35% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Propanc Biopharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.53+$0.06 (+13.97%)
Cell Source, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.45% below the high.
CA$0.31+CA$0.02 (+5.08%)
Telescope Innovations Corp.’s quoted price sits in the lower half of its reported 52-week range, 71.82% below the high.
$1.15$0.00 (0.0%)
HOOKIPA Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.81% below the high.
$0.08$0.00 (0.0%)
EOM Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.22% below the high.
CA$0.02CA$0.00 (0.0%)
PreveCeutical Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.03$0.00 (0.0%)
Quest PharmaTech Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.23% below the high.
$0.05$0.00 (0.0%)
Gemina Laboratories Ltd.’s quoted price sits in the lower half of its reported 52-week range, 85.46% below the high.
$0.01$0.00 (0.0%)
Sirona Biochem Corp.’s quoted price sits in the lower half of its reported 52-week range, 57.85% below the high.
